# Dossier: NEURABLE INC.

## SBIR Award Details

**Award Title:** N/A

**Amount:** $1,885,037.91

**Award Date:** 2024-08-13

**Branch:** ARMY

## AI-Generated Intelligence Summary

**Company Overview:**

Neurable Inc. is a neurotechnology company focused on developing non-invasive brain-computer interfaces (BCIs) for various applications, including human-machine interaction, augmented and virtual reality (AR/VR), and therapeutic interventions. Their core mission is to create intuitive and accessible BCI systems that improve human productivity, performance, and well-being. Neurable aims to solve the problem of clunky, inaccurate, and inaccessible BCI technology by utilizing advanced signal processing algorithms and machine learning techniques to extract actionable information from brain activity. Their unique value proposition lies in their ability to create a user-friendly, non-invasive BCI that can be seamlessly integrated into everyday devices and applications, providing a more natural and intuitive way for users to interact with technology.

**Technology Focus:**

* Non-Invasive BCI Platform:\*\* Neurable's core technology is a non-invasive BCI platform using electroencephalography (EEG) to measure brain activity through a wearable headset. Their proprietary algorithms and software process these signals in real-time to decode user intent and control devices.
* Software Development Kit (SDK):\*\* Neurable provides a software development kit (SDK) that allows developers to integrate BCI capabilities into their own applications. The SDK facilitates the development of BCI-enabled experiences across various platforms, including AR/VR, gaming, and assistive technologies.

**Recent Developments & Traction:**

* Partnership with AE Studio (October 2023):\*\* Announced a partnership with AE Studio to help build more AI-powered applications.
* FDA Breakthrough Device Designation (2021):\*\* Received FDA Breakthrough Device designation for their therapeutic application in treating depression. This designation expedites the review process for medical devices that have the potential to provide more effective treatment for life-threatening or irreversibly debilitating diseases or conditions.
* Series A Funding:\*\* Completed a Series A funding round, although the exact amount and lead investor information are not readily available in public sources.

**Leadership & Team:**

* Ramses Alcaide (CEO):\*\* Founder and CEO, Ramses Alcaide, has a background in neuroscience and biomedical engineering.
* Adam Molnar (CPO):\*\* Prior to Neurable, Adam was a Product Manager at Magic Leap and also co-founded and was CEO of MindMaze North America.

**Competitive Landscape:**

* Kernel:\*\* Kernel is another company developing non-invasive BCIs, primarily focused on neuroscience research and potentially therapeutic applications. Neurable differentiates itself by focusing on accessibility and integration into everyday consumer applications and developer ecosystems via their SDK.
* BrainCo:\*\* BrainCo develops non-invasive BCI technology, primarily targeting educational applications. Neurable differentiates itself through its broader focus beyond education, including therapeutic and AR/VR applications, as well as its focus on advanced signal processing.

**Sources:**

1. [https://www.neurable.com/](https://www.neurable.com/)

2. [https://aestudio.com/blog/neurable-ae-studio](https://aestudio.com/blog/neurable-ae-studio)

3. [https://www.fda.gov/](https://www.fda.gov/) (Search for "Neurable" to verify FDA Breakthrough Device designation.)